RFK Jr. Moves to End FDA Peptide Ban: What 14 Compounds and a July Deadline Mean

What Happened

In April 2026, Health Secretary Robert F. Kennedy Jr. told Joe Rogan’s podcast audience that FDA would soon remove 14 of the 19 peptides on its “do not formulate” list — compounds FDA prohibited compounding pharmacies from producing after a 2023 rulemaking.

Days later, FDA made it official: a July 23–24, 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting will formally evaluate seven peptides for possible inclusion on the 503A bulk substances list. The agency also announced it would remove the compounds from the “significant safety risks” list in the interim, before the panel convenes.

This is a direct policy reversal from the Biden-era FDA, which added ~20 peptides to the restricted list after its own advisory panel voted overwhelmingly that the compounds were too risky to compound.

The July 23-24 PCAC Agenda

The formal agenda divides across two days:

Day 1 — July 23:

• BPC-157 (free base and acetate) — under review for ulcerative colitis
• KPV — under review for wound healing
• TB-500 (Thymosin Beta-4 fragment) — under review for wound healing
• MOTS-C — under review for metabolic conditions

Day 2 — July 24:

• Emideltide (DSIP) — Delta Sleep-Inducing Peptide
• Semax — nootropic/neuroprotective ACTH analog
• Epitalon — pineal peptide, longevity claims

A second group of compounds — CJC-1295, Ipamorelin, Thymosin Alpha-1, AOD-9604, and Selank — was referred to PCAC in September 2024 and is scheduled for review at a separate meeting before February 2027.

The Political Context

Several of the FDA advisers and staff who oversaw the original 2023 and 2024 decisions have since left the agency. The FDA’s pharmacy panel currently has vacancies — which Kennedy could fill with allies before the July meeting convenes.

Former FDA official Dr. Peter Lurie, now at the Center for Science in the Public Interest, said the outcome was effectively predetermined: “Everybody knows the outcome that the secretary wants.” He described the proceedings as a “profound threat” to FDA’s drug approval framework, arguing that a lower-rigor compounding pathway undermines incentives for formal clinical development.

On the other side, Kennedy’s argument — that the original ban created a “dangerous black market” — is not implausible. Demand for these compounds didn’t disappear when compounding was restricted; it shifted to gray-market suppliers with no quality controls.

What Prescribers Need to Know Now

Interim removal from the safety risk list is not the same as 503A listing. FDA’s announcement that it will remove these compounds from the high-risk list before the July meeting is a de-escalation, but it does not authorize compounding. 503A pharmacy dispensing still requires the compound to be on the approved bulk substances list, which requires PCAC recommendation and FDA action.

The PCAC recommendation is non-binding. FDA follows advisory panel recommendations most of the time, but not always. The current political environment makes a favorable recommendation more likely — but the formal 503A listing process has additional steps after PCAC.

Evidence quality still matters for your practice. Regardless of regulatory status, the evidence base for these compounds hasn’t changed. BPC-157’s human trial data remains sparse (the Croatian IBD Phase II results are still unpublished). MOTS-C has no Phase II human data at all for its reviewed indication. A regulatory green light is not the same as clinical validation.

Comment window is open. The federal docket for this PCAC meeting accepts public comment. If you have clinical observations — positive or negative — about any of these compounds, this is a genuine input opportunity. Watch the Federal Register for the formal public comment deadline.

The Compounds Not on the July Agenda

Kennedy said he wants to unban 14 of the original 19. The July PCAC covers 7. The remaining 7 in the first wave (plus the 5 in the 2024 referral cohort for the separate meeting) account for his stated total.

The five compounds in the second PCAC cohort — CJC-1295, Ipamorelin, Thymosin Alpha-1, AOD-9604, Selank — are some of the most clinically relevant. Ipamorelin and CJC-1295 are among the most widely prescribed compounded peptides in functional medicine. Thymosin Alpha-1 has regulatory approval in 35+ countries. Their review timeline before February 2027 is less defined.

Bottom Line

The July 23-24 PCAC meeting is real and the regulatory direction is clear: the current administration wants these compounds available for compounding. The procedural path — PCAC review, FDA action on the 503A list — takes time, but the political will is explicit.

For prescribers, the key watch items are: (1) whether PCAC votes favorably, (2) how quickly FDA acts on the list post-PCAC, and (3) whether the interim removal from the safety risk list changes near-term enforcement posture.

We’ll cover July 23-24 in real time. Subscribe to the Ercle newsletter for updates as the panel convenes.